Watchdog Blog

Likely DOJ Nominee Has Long History of Lobbying Against Consumer Rights

We've been keeping a close watch over the Obama Administration's potential nominees to ensure that members of the new administration will be advocates for consumer and taxpayer rights.

We recently issued an investigative report on Mark Gitenstein, a longtime corporate lobbyist, who may get the nod to head the DOJ's Office of Legal Policy.

Gitenstein's long list of corporate lobbying activities appear to directly violate President Obama's ethics policy prohibiting executive branch employees from becoming appointed to "issue areas" in which they have acted as lobbyists within the last two years.  A closer look at Gitenstein's lobbying reveals that he has sought to weaken or eliminate vital consumer protections, including the False Claims Act, which has saved billions of taxpayer dollars, and access to court to hold corporations accountable for bad behavior.

Gitenstein's past actions seem to be in stark contradiction with Obama's executive order governing conflicts of interest, and clash with Obama's regular calls for more accountability for government and corporations alike.

Public Citizen sent a letter to Obama raising concerns about Gitenstein's long history of corporate lobbying activities, and suggesting that the possible nomination be reconsidered.  We also joined forces with the Project on Government Oversight, Government Accountability Project, and other noteworthy organizations to make the Senate Judiciary Committee aware that this potential candidate does not have our endorsement.

FDA Puts BPA Under Further Review

A couple of weeks ago, we decried the FDA's cozy relationship with industry in its announcement that the safety of products containing BPA was "adequate." It looks like we weren't the only ones who noticed. Friday, an advisory panel agreed that the FDA's report created "a false sense of security" regarding the safety of BPA. According to the Washington Post, the toxicologists on the panel "said the FDA had relied too heavily on studies funded by the chemical industry to make its decision." The FDA deserves credit for taking a second look at the science behind its decision, but this whole episode only further demonstrates that the danger of our federal agencies outsourcing their work to the industries they regulate – a trend the Obama administration should look to reverse.